Finding New Targets for Cancer Drugs: Kevin Parker on The Long Run

Kevin Parker is today’s guest on The Long Run.

Kevin Parker, co-founder and CEO, Cartography Biosciences

Kevin is the co-founder and CEO of South San Francisco-based Cartography Biosciences. The company is using multi-omic tools to map out which targets are specifically expressed on cancer cells. The idea is to find new, precise targets that antibody drugs can aim for.

Cartography got started during the pandemic, raised a $57 million Series A round in the summer of 2022, and last year formed a partnership with Gilead Sciences.

Now, please join me and Kevin Parker on The Long Run.